OC-0060 I-SABR induces local and abscopal responses in metastatic patients after failure to ICI treatment

Chicas-Sett, Rodolfo; Morales-Orue, Ignacio; Castilla-Martinez, Juan; Blanco, Jesús; Kannemann, A.; Zafra, J.; Zając, M; Lloret, M.; Lara, P.C.

doi:10.1016/s0167-8140(19)30480-3

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary results are promising, with an AE rate of 33% and an ORR of 53%. Of particular interest is the fact that, in this study, all patients had failed to ICI monotherapy but could maintain this same treatment until new progression by adding SABR [56].…”

Section: Can This Retrospective Data Be Replicated In Clinical Trials?mentioning

confidence: 95%

Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent

Chicas-Sett

Zafra-Martín

Morales-Orue³

et al. 2020

Cancers

View full text Add to dashboard Cite

Lung cancer is one of the main causes of cancer-related mortality worldwide. Over the years, different therapeutic modalities have been adopted depending on tumor stage and patient characteristics, such as surgery, radiotherapy (RT), and chemotherapy. Recently, with the development of immune-checkpoint inhibitors (ICI), the treatment of metastatic and locally advanced non-small cell lung cancer (NSCLC) has experienced a revolution that has resulted in a significant improvement in overall survival with an enhanced toxicity profile. Despite this paradigm shift, most patients present some kind of resistance to ICI. In this setting, current research is shifting towards the integration of multiple therapies, with RT and ICI being one of the most promising based on the potential immunostimulatory synergy of this combination. This review gives an overview of the evolution and current state of the combination of RT and ICI and provides evidence-based data that can improve patient selection. The combination in lung cancer is a safe therapeutic approach that improves local control and progression-free survival, and it has the potential to unleash abscopal responses. Additionally, this treatment strategy seems to be able to re-sensitize select patients that have reached a state of resistance to ICI, further enabling the continuation of systemic therapy.

show abstract

Section: Can This Retrospective Data Be Replicated In Clinical Trials?mentioning

confidence: 95%

Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent

Chicas-Sett

Zafra-Martín

Morales-Orue³

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Similarly, clinical benefits from the combination of ICI and radiotherapy in metastatic NSCLC have been validated in preclinical and clinical evidence. Combination of immunotherapy and SABR (I-SABR) can reactivate the immune system of patients undergone progression to ICI monotherapy and thus enhancing patients’ distant tumor control and clinical benefits ( 43 ). A randomized multicenter phase 2 study (PEMBRO-RT) enrolled 92 patients with advanced NSCLC and divided them into experiment arm (Pembrolizumab after SBRT of 8 Gy×3) and control arm (Pembrolizumab alone).…”

Section: Combination Of Radiotherapy and Immunotherapy In Nsclcmentioning

confidence: 99%

“…It indicates that radiotherapy has a potential to drive the regression of distant tumors together with immunotherapy (38). The combination of radiotherapy and ICIs has shown to improve the opportunity to boost abscopal response rates, ranging from 23% to 38%, compared with immunotherapy or radiotherapy alone in multiple clinical trials (38)(39)(40)(41)(42)(43). In addition, a volume of preclinical studies added immune-stimulative drug to radiotherapy, such as immunoadjuvant FMS-like tyrosine kinase receptor 3 ligand (sFLT3L) (44), DCs (45), granulocytemacrophage colony-stimulating factor (GM-CSF) (46), CTLA-4 blockades (47,48), PD-1/PD-L1 blockades (2,25).…”

Section: The Abscopal Effectmentioning

confidence: 99%

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients

Meng

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Radiotherapy is an effective local treatment modality of NSCLC. Its capabilities of eliminating tumor cells by inducing double strand DNA (dsDNA) damage and modulating anti-tumor immune response in irradiated and nonirradiated sites have been elucidated. The novel ICIs therapy has brought hope to patients resistant to traditional treatment methods, including radiotherapy. The integration of radiotherapy with immunotherapy has shown improved efficacy to control tumor progression and prolong survival in NSCLC. In this context, biomarkers that help choose the most effective treatment modality for individuals and avoid unnecessary toxicities caused by ineffective treatment are urgently needed. This article summarized the effects of radiation in the tumor immune microenvironment and the mechanisms involved. Outcomes of multiple clinical trials investigating immuno-radiotherapy were also discussed here. Furthermore, we outlined the emerging biomarkers for the efficacy of PD-1/PD-L1 blockades and radiation therapy and discussed their predictive value in NSCLC.

show abstract

OC-0060 I-SABR induces local and abscopal responses in metastatic patients after failure to ICI treatment

Cited by 2 publications

References 0 publications

Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent

Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients

Contact Info

Product

Resources

About